Respiratory Syncytial Virus (RSV) is a very contagious virus and the most common cause of
lower respiratory tract infections such as bronchiolitis and pneumonia in infants. By the age
of two years, nearly all infants will be infected with RSV at least once. Globally, it is a
leading cause of hospitalisations among young infants with approximately 33 million cases of
acute lower respiratory infections causing more than three million hospitalisations each year
in children younger than 5 years. While most RSV cases are mild, one can't predict which
infants could get seriously ill and end up in hospital. This is because the course of the
disease is unpredictable.
When the RSV infection of the child is severe and associated with hospitalisation, it may
lead to intensive care unit admissions with use of supportive care such as mechanical
ventilation. It may further result in long-term complications such as recurrent wheezing,
reduced pulmonary function and asthma. Moreover, RSV-related hospitalisations can be
associated with a significant burden on the entire family, causing considerable stress and
increased loss of work productivity. Currently, there is a lack of adequate information on
how severe RSV infection leading to hospitalisation of infants (< 2 years) impacts the
quality of life of affected families.
To close this knowledge gap, the ResQ Family research project was initiated: ResQ Family:
Impact of Respiratory Syncytial Virus (RSV) hospitalisation on Quality of life of Families -
a multi-country study. The project runs from December 2021 until June 2024 and covers four
European countries: France, Germany, Italy and Sweden. Data will be collected between autumn
2022 and spring 2023, corresponding to a typical RSV season duration in temperate countries
in the northern hemisphere.
The aim of the ResQ Family study is to find out how infant RSV hospitalisation impacts the
quality of life of affected children and their families. The goal is further to provide
scientific evidence on the burden of RSV and raise awareness among all relevant stakeholders
including healthcare professionals and patient representatives, decision-makers and the
general public.
An online questionnaire will be used to ask parents and caregivers of children experiencing
(or having recently experienced) hospitalisation due to RSV infection to share their
experiences and a follow-up will take place after six weeks. The study focuses on children up
to 24 months with a hospital stay due to RSV infection of at least 12 hours in total. The
hospital admission should not be longer than 4 weeks ago.
Experienced researchers and health care professionals renowned in the field of RSV as well as
parent/patient representatives support the project as part of an external scientific advisory
board and a project expert group.
EFCNI received a research grant from Sanofi in support of this independent study.